BMS-986141

• Description:

  BMS-98614 is an orally active, selective thrombin receptor protease-activated receptor-4 (PAR-4) antagonist with an IC50 value of 0.4 nM. BMS-98614 has excellent antithrombotic effect[1][2].

• UNSPSC:

  12352005

• Target:

  Protease Activated Receptor (PAR)

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/bms-986141.html

• Purity:

  98.86

• Solubility:

  DMF : 8.33 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C(N(C)C)C1=CC=C(C2=NC(COC3=C4C=C(C5=CN6C(SC(OC)=N6)=N5)OC4=CC(OC)=C3)=CS2)C=C1

• Molecular Formula:

  C27H23N5O5S2

• Molecular Weight:

  561.63

• References & Citations:

  [1]E Scott Priestley, et al. Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4. J Med Chem. 2022 Jul 14;65 (13) :8843-8854.|[2]P Wong, et al. Favorable therapeutic index of an orally-active small-molecule antagonist of the platelet protease-activated receptor-4, BMS-986141, compared with the P2Y12 antagonist ticagrelor in cynomolgus monkeys. European Heart Journal, Volume 41, Issue Supplement_2, November 2020.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• Isoform:

  PAR4

• CAS Number:

  [1478711-48-6]